Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.60
-0.41 (-1.58%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Mineralys Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-370.79-170.6-192.4-84.66-31.48-18.73
Net Income
-349.58-154.65-177.81-71.9-29.8-19.41
Earnings Per Share
-4.38-2.29-3.66-1.99-5.77-3.89
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
661.41656.64198.19236.57110.1110.61
Total Debt
97.62-----
Net Cash (Debt)
563.8656.64198.19236.57110.1110.61
Net Cash Growth
73.52%231.32%-16.22%114.85%937.60%-
Net Cash Per Share
7.069.714.086.5421.312.13

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-138.79-142.42-166.31-81.17-29.22-14.56
Capital Expenditures
-0.02-0.02-0.1---
Free Cash Flow
-138.8-142.43-166.41-81.17-29.22-14.56
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.